Clover joins COVID-19 vaccine party with Chinese launch

Chinese biotech Clover Biopharmaceuticals (HKEX: 02197) has launched its protein-based COVID-19 vaccine in China.

The first doses of the recombinant SARS-CoV-2 subunit vaccine have been delivered and administered in Changxing, Zhejiang, as part of the campaign for China’s second booster dose and fourth jab overall, targeting older adults, immuno-compromized people and those with comorbidities.

Joshua Liang, chief executive and executive director of Clover, said: “We are very proud to be delivering on our commitment to help protect the elderly and other vulnerable populations with our premium COVID-19 booster vaccine, and commencing the launch in Zhejiang province where our vaccine is manufactured.”